- Home
- AZN
AZN
AstraZeneca PLC
as 04-17-2025 4:00pm EST
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
| Founded: | 1992 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 205.5B | IPO Year: | 1993 |
| Target Price: | $89.75 | AVG Volume (30 days): | 6.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 4.50 | EPS Growth: | 18.11 |
| 52 Week Low/High: | $61.24 - $87.68 | Next Earning Date: | 04-29-2025 |
| Revenue: | $54,073,000,000 | Revenue Growth: | 18.04% |
| Revenue Growth (this year): | 8.64% | Revenue Growth (next year): | 6.11% |
Latest AstraZeneca PLC News
AZN Breaking Stock News: Dive into AZN Ticker-Specific Updates for Smart Investing
Bloomberg
18 hours ago
Lilly Soars After Weight-Loss Pill Results Rival Ozempic’s
Insider Monkey
3 days ago
Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth?
Reuters
3 days ago
Tariff wars to hit popular US-made drugs in China, regulator data shows
Insider Monkey
4 days ago
Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires?
Motley Fool
4 days ago
Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now
Zacks
4 days ago
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis
Zacks
7 days ago
Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More
Pharmaceutical Technology
7 days ago
AstraZeneca’s oral breast cancer drug Truqap greenlit for NHS use
Compare AZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AZN AstraZeneca PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.